Suchergebnisse
![[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche setzt starke Dynamik in erstem Halbjahr 2026 mit Umsatzwachstum von +6% zu konstanten Wechselkursen fort; -2% in CHF aufgrund deutlicher Aufwertung des Schweizer FrankensPhoto, wide shot, wide-angle lens, soft focus, Pharmaceutical company, sunset photo at golden hour, photo by Peter Lik: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-TIgKJfhK8q44RPNTTsL9npu7.png?st=2023-05-08T05%3A58%3A04Z&se=2023-05-08T07%3A58%3A04Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-08T02%3A36%3A56Z&ske=2023-05-09T02%3A36%3A56Z&sks=b&skv=2021-08-06&sig=BDDjRcmCPf%2BH//HSxRGZYByMqOKev8lx0/Dhvka/lXk%3D](https://www.sharewise.com/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsiZGF0YSI6NzAxMzE0MiwicHVyIjoiYmxvYl9pZCJ9fQ==--f2ab63ff218591ef3bb67d46faa3aab8fd344eea/eyJfcmFpbHMiOnsiZGF0YSI6eyJmb3JtYXQiOiJwbmciLCJyZXNpemUiOiIzNTB4In0sInB1ciI6InZhcmlhdGlvbiJ9fQ==--e9f9df916cd0c94213bf1ed72aa6621e3bf605c9/lXk-3D.png?locale=de)
[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche setzt starke Dynamik in erstem Halbjahr 2026 mit Umsatzwachstum von +6% zu konstanten Wechselkursen fort; -2% in CHF aufgrund deutlicher Aufwertung des Schweizer Frankens
- Konzernverkäufe stiegen in den ersten sechs Monaten um 6% zu konstanten Wechselkursen (CER1; in CHF ausgewiesen -2% und auf USD-Basis2 8%) aufgrund hoher Nachfrage nach innovativen Medikamenten
Roche H1 Sales Decline on Currency Headwinds, Key Drugs Keep Momentum
Swiss pharma giant Roche Holding AG RHHBY reported sales of CHF 30.4 billion ($38.6 billion) in the first half of 2026, down 2% year over year due to the significant appreciation of the Swiss franc.
The Hanover Insurance Group Q2 Earnings Call Highlights
The Hanover Insurance Group (NYSE:THG) reported record second-quarter operating performance, citing improved underwriting margins, accelerating premium growth and higher investment income across
Alnylam Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Alnylam Pharmaceuticals, Inc.? Here are five stocks we like better.
- Second-quarter revenue surged 74% to approximately $1.2 billion, driven by AMVUTTRA, which
Madrigal Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Madrigal Pharmaceuticals, Inc.? Here are five stocks we like better.
- Rezdiffra sales rose 71% year over year to $364.3 million in Q2 2026, with nearly $1.3 billion in
Recursion Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Recursion Pharmaceuticals, Inc.? Here are five stocks we like better.
- Recursion advanced its pipeline, moving its first neuroscience target from the Roche/Genentech